Physicians | Molecular Health

Physicians

No two tumors are alike, and every treatment ought to be just as specific.

How you can use Molecular Health Guide to identify the appropriate drug-based treatment options for your patients – from the very beginning.

Physicians

No two tumors are alike, and every treatment ought to be just as specific.

How you can use Molecular Health Guide to identify the appropriate drug-based treatment options for your patients – from the very beginning.

Precision medicine in oncology

We know that doctors always try to base their decisions about the best-possible treatment for a given patient based not only on the diagnosis itself. They also incorporate information about the patient’s characteristics, such as age, physical constitution, the desire to have a child, and, if appropriate, family medical history.

 

What is new is that modern diagnostics allow physicians to document the genetic, molecular and cellular characteristics of each patient and use this information to make decisions about whether a given treatment is an option. This is how personalized medicine complements oncological treatment as it has been practiced to date. 

Logo of MH Mendel
CE Logo
Logo of IVD
TÜV Logo

How you can make customized therapeutic decisions based on molecular genetics

Working with DNA sequences, Molecular Health transforms genetic patient data into clinically viable information so that the most efficacious and safest drug-based option can be determined for every oncology patient.

  • Patient-specific information from the genetic material of the tumor is compared with the latest knowledge published in biomedical journals.
  • References are provided to recruiting clinical studies which correspond to the patient’s indication.

 

 

Matching Icon
  • A comprehensive molecular-genetic tumor profile is created as the basis for subsequent analysis and customized therapeutic options.

     

  • The drug safety risk factors (resistance and toxicity biomarkers) are analyzed.

 

 

Profiling Icon
  • There is complete transparency about the approval and development status of study drugs as well as information about approved drugs and biomarkers 

  • The report can be enhanced and complemented by your own expertise 

 

Profiling Icon

Tumor profiling

MH Guide analyses rely on data about the tumor which are derived from sequencing the genetic material. Depending on the tumor and staging, there are two potential procedures:

focuses on a set of over 600 genes defined by Molecular Health. This panel was selected based on its medical significance and therapeutic relevance in oncology. The analysis facilitates hypotheses about intelligent drug-based therapeutic options and risk factors when selecting particular active substances, and this serves as the basis for a customized treatment plan.

expands the analysis to include the complete set of over 20,000 functional genes – all of the regions which contain protein-coding genes. In addition to the information that can be derived from the MH Guide panel, this analysis provides information about complex contexts between individual genetic mutations, drug efficacy and mechanisms of disease.

How you as an oncologist can benefit from the use of MH Guide

Selecting the appropriate drug-based therapy from a comprehensive report

 

Preventing severe or more common adverse effects and unnecessary treatments



Optimizing therapeutic decisions for patients in advanced stages of the disease or for those who have exhausted the possibilities of standard treatments.

Informing you about relevant clinical trials for your patients 

 


Molecular Health Button
Molecular Health Button
Molecular Health Button
Molecular Health Button

How you as an oncologist can benefit from the use of MH Guide

Selecting the appropriate drug-based therapy from a comprehensive report

Molecular Health Button

Preventing severe or more common adverse effects and unnecessary treatments

 

Molecular Health Button

Optimizing therapeutic decisions for patients in advanced stages of the disease or for those who have exhausted the possibilities of standard treatments.

Molecular Health Button

Informing you about relevant clinical trials for your patients 

 

Molecular Health Button

The step-by-step procedure for you as the treating physician

As the treating physician, you first meet with your patient to discuss the option of a DNA analysis of the tumor using MH Guide.

Once you conducted the consultation with your patient you contact an MH Guide-certified colleague to discuss the next steps in preparing the analysis. Our Customer Care Team can assist you in initiating this contact.

Preparing the analysis

You receive all of the relevant information and forms needed to prepare the analysis.

Logo of Step by Step

The MH Guide-certified physician sends the order for sequencing the tumor DNA and the subsequent MH Guide analysis. The following tasks are coordinated with your assistance:

  • Conducting patient-information discussions and receiving written consent for a genetic analysis as mandated by the German Genetic Diagnostic Act. 
  • Organizing the sample-preparation process as described in the sample-collection process.
  • Coordinating the logistics. 

You discuss the findings and therapeutic options with your patient as well as talking about potentially taking part in suitable clinical trials.

In a certified laboratory, the DNA of the samples is decoded by means of next-generation sequencing. The sequencing data are transferred to Molecular Health via secure data access

Findings

The sequencing data are analyzed along with the clinical patient data at Molecular Health to define the tumor’s characteristics. The MH Guide-certified physician then generates a report and presents it to the treating physician as a qualified treatment recommendation.

Who pays for a MH Guide analysis?

Depending on country-specific regulations and on the cancer entity, an MH Guide analysis and the underlying NGS assay is reimbursed. Reimbursement is either a standard or initiated per additional extra request by your patient. If it is not reimbursed, the patient may want to cover the costs by him- or herself.

Please contact us for more information: CustomerCareEU@molecularhealth.com 

Certification program for physicians in oncology

Are you a physician who is interested in becoming an MH Guide-certified physician?

Then join our certification program for physicians in oncology by requesting information!
 

In order to use a medical device such as MH Guide, you need to take part in a certification training where you learn how to use and apply the software. As an MH Guide user, you can always turn to our Customer Care Team for any organizational matters. For any technical matters or questions, you can consult directly with our Scientific Field Support Team of scientists with doctoral degrees. 

 

As our mission is to serve patients and physicians with high quality products and services we are seeking for continuous improvement and, therefore, we appreciate your valuable input and suggestions about new product features and content that will help us optimize MH Guide.   

 

 

Phone EU: +49 6221 43851-150
E-Mail: CustomerCareEU@molecularhealth.com

MH Guide Logo

Our powerful applications for treatment decision support

MH Guide Logo


MH Guide i
dentifies safe and effective therapies for patients by analyzing the molecular profile.It matches detected mutations to the world’s knowledge in the field of oncology and hereditary diseases and helps medical experts to create a patient-specific clinical report. MH Guide is an IVD registered in the EU.







Molecular Health Guide Mendel (MH Mendel) supports human geneticists to identify clinically significant genetic variants and create a diagnostic report for individual patients.
MH Mendel is part of the Molecular Health Guide (MH Guide) solution which is an IVD registered in the EU.




Logo of MH BRCA


Molecular Health Guide BRCA (MH BRCA) supports medical professionals in identifying and reporting clinically significant germline variants associated with hereditary breast and ovarian cancer (HBOC) syndrome from NGS-based assessment of BRCA1 and BRCA2 and other HBOC related genes. MH BRCA is part of the Molecular Health Guide (MH Guide) solution which is an IVD registered in the EU.

 

Let’s talk about how our technology can work for you

To find out more, you can call our customer care team or help desk or send us an e-mail. We would be delighted to provide you with more information or answer your questions.


EU: +49 6221 43851-150
E-Mail: CustomerCareEU@molecularhealth.com